多疗程碘[^(131)I]-间碘苄胍治疗多部位转移性副神经节瘤1例  

Multi-course Iodine-131-meta-iodobenzylguanidine in the treatment of metastatic paraganglioma:a case report

作　　者：李赟 高洪波 李隆敏 邵玉军 祝夏阳 Li Yun;Gao Hongbo;Li Longmin;Shao Yujun;Zhu Xiayang(Department of Radionuclide Treatment Center,Beijing Nuclear Industry Hospital,Beijing 102413,China)

机构地区：[1]北京核工业医院核素诊疗中心,北京102413

出　　处：《中国综合临床》2024年第2期114-119,共6页Clinical Medicine of China

基　　金：中国宝原科研基金项目(ZGBYKY-2021-002)。

摘　　要：副神经节瘤(paraganglioma,PGL)是一种引起内分泌性高血压的少见神经内分泌肿瘤,所有副神经节瘤均具有转移潜能。转移性副神经节瘤患者5年存活率<50%,治疗是较大的难题。转移性PGL对碘[^(131)I]-间碘苄胍(^(131)I-meta-iodobenzylguanidine,^(131)I-MIBG)具有较高的特异性摄取,因此治疗效果佳、耐受性良好、不良反应少,但目前国内暂缺少相关详细临床诊疗数据。现报道1例多部位转移性副神经节瘤多疗程^(131)I-MIBG详细诊治经过,并探讨其治疗效果、安全及耐受性,供临床参考。Paraganglioma(PGL)is a rare neuroendocrine tumor that causes endocrine hypertension.All paragangliomas had metastatic potential.The 5-year survival rate of patients with metastatic paraganglioma is less than 50%,and the treatment is a big problem.Metastatic PGL has a high specific uptake of iodine[^(131)I]-meta-iodobenzylguanidine(^(131)I-MIBG),so the treatment is effective,well tolerated,and has few adverse reactions.However,there is a lack of relevant detailed clinical diagnosis and treatment data in China.This article reports the diagnosis and treatment of a case of multi-site metastatic paraganglioma with multiple courses of^(131)I-MIBG,and discusses the efficacy,safety and tolerance of the treatment for clinical reference.

关 键 词：副神经节瘤 转移 碘[^(131)I]-间碘苄胍 

分 类 号：R739.4[医药卫生—肿瘤]